Biowaiver monographs for immediate release solid oral dosage forms: Furosemide

Journal of Pharmaceutical Sciences

Volumn 99, Issue 6, 2010, Pages 2544-2556

  Granero, G E ^a   Longhi, M R ^a   Mora, M J ^a   Junginger, H E ^b   Midha, K K ^c   Shah, V P ^d   Stavchansky, S ^e   Dressman, J B ^f   Barends, D M ^g  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b NARESUAN UNIVERSITY   (Thailand)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d International Pharmaceutical Federation FIP   (Netherlands)

^e UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^f GOETHE UNIVERSITY   (Germany)

^g NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Absorption; Bioequivalence; Biopharmaceutics classification system (BCS); Furosemide; Permeability; Regulatory science; Solubility

Indexed keywords

APHAR; BEXAL; CINFA; DIURAPID; DIUSEMIDE; EXCIPIENT; FUROBETA; FUROGAMMA; FUROMIN; FUROSAL; FUROSEMIDE; JUFURIX; ROSEFUR; UNCLASSIFIED DRUG;

ALKALOSIS; AREA UNDER THE CURVE; BIOEQUIVALENCE; CHRONIC KIDNEY DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MANUFACTURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; EDEMA; ELECTROLYTE DISTURBANCE; HUMAN; HYPERTENSION; HYPOCHLOREMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; MUSCLE CRAMP; NONHUMAN; NOTE; PARTITION COEFFICIENT; PKA; SIDE EFFECT; STEREOISOMERISM; THIRST; UNSPECIFIED SIDE EFFECT; WEAKNESS; XEROSTOMIA;

EID: 77951629023     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22030     Document Type: Note

References (101)

1. Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Möller H, Olling M, Shah VP, Barends DM. 2004. Biowaiver monographs for immediate release solid oral dosage forms based on Biopharmaceutics Classification System (BCS). Literature data: Verapamil Hydrochloride, Propranolol Hydrochloride, and Atenolol. J Pharm Sci 93:1945-1956. (Pubitemid 39045477)
2. Kalantzi L, Reppas C, Dressman JB, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky SA, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Acetaminophen (Paracetamol). J Pharm Sci 95:4-14.
3. Granero GE, Longhi MR, Becker C, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Acetazolamide. J Pharm Sci 97:3691-3699. (Pubitemid 46087336)
4. Arnal J, Gonzalez-Alvarez I, Bermejo M, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Aciclovir. J Pharm Sci 97:5061-5073. (Pubitemid 46087336)
5. Manzo RH, Olivera ME, Amidon GL, Shah VP, Dressman JB, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Amitriptyline Hydrochloride. J Pharm Sci 95:966-973. (Pubitemid 43731760)
6. Verbeeck RK, Junginger HE, Midha KK, Shah VP, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride. J Pharm Sci 94:1389-1395.
7. Jantratid E, Prakongpan S, Dressman JB, Amidon GL, Junginger HE, Midha KK, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Cimetidine. J Pharm Sci 95:974-984. (Pubitemid 43723158)
8. Chuasuwan B, Binjesoh V, Polli JE, Zhang H, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2009. Biowaiver monographs for immediate release solid oral dosage forms: Diclofenac sodium and diclofenac potassium. J Pharm Sci 98:1206-1219.
9. Jantratid E, Strauch S, Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2009. Biowaiver monographs for immediate release solid oral dosage forms: Doxycycline hyclate. J Pharm Sci Epub ahead of print.
10. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Ethambutol dihydrochloride. J Pharm Sci 97:1350-1360.
11. Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP, Vogelpoel H, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms: Ibuprofen. J Pharm Sci 94:2121-2131. (Pubitemid 41670501)
12. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Isoniazid. J Pharm Sci 96:522-531. (Pubitemid 46469925)
13. Stosik AG, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Metoclopramide hydrochloride. J Pharm Sci 97:3700-3708.
14. Vogt M, Derendorf H, Krämer J, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Prednisolone. J Pharm Sci 96:27-37. (Pubitemid 46087336)
15. Vogt M, Derendorf H, Krämer J, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Prednisone. J Pharm Sci 96:1480-1489. (Pubitemid 46953764)
16. Becker C, Dressman JB, Junginger HE, Kopp S, Shah VP, Stavchansky S, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Pyrazinamide. J Pharm Sci 97:3709-3720. (Pubitemid 46087336)
17. Grube S, Langguth P, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2009. Biowaiver monographs for immediate release solid oral dosage forms: Quinidine sulfate. J Pharm Sci 98:2238-2251.
18. Kortejärvi H, Yliperttula M, Dressman JB, Junginger HE, Midha KK, Shah VP, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms: Ranitidine hydrochloride. J Pharm Sci 94:1617-1625. (Pubitemid 41360858)
19. Becker C, Dressman JB, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2009. Biowaiver monographs for immediate release solid oral dosage forms: Rifampicine. J Pharm Sci 98:2252-2267. (Pubitemid 46087336)
20. Sweetman S, editor. 2009. Martindale: The complete drug reference. Electronic version. Pharmaceutical Press, Thomson/MICROMEDEX, London, UK/Greenwood Village, Colorado.
21. Shin S-C, Kim J. 2003. Physicochemical characterization of solid dispersion of furosemide with TPGS. Int J Pharm 251:79-84. (Pubitemid 36071462)
22. Rowbotham PC, Stanford JB, Sugden JK. 1976. Some aspects of the photochemical degradation of frusemide. Pharm Acta Helv 51:304-307.
23. Devarakonda B, Otto DP, Judefeind A, Hill RA, de Villiers M. 2007. Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes. Int J Pharm 345:142-153. (Pubitemid 350087542)
24. Maestrelli F, Garcia-Fuentes M, Mura P, Alonso MJ. 2006. A new nanocarrier consisting of chitosan and hydroxypropylcyclodextrin. Eur J Pharm Biopharm 63:79-86. (Pubitemid 43792439)
25. Motz SA. 2007. Combined assessment of dissolution and epithelial permeability of solid oral dosage forms. Ph.D Thesis Universität Saarland. http://deposit.ddb.de/cgi-bin/dokserv?-idn=983385645&dok-var=d1&dok-ext= pdf&filename=&filename=983385645.pdf (accessed May 18, 2009).
26. WHO. 2006. Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability. Technical Report Series, No.937, 40th Report, Annex 7 of WHO Expert committee on specifications for pharmaceutical preparations. http://whqlibdoc.who.int/trs/WHO-TRS-937-eng. pdf. (accessed May 18, 2009).
27. FDA. 2000. Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. US Food and Drug Administration, Center for Drug Evaluation and Research, USA. http://www.fda.gov/cder/guidance/3618fnl. pdf. (accessed May 18, 2009).
28. EMEA. 2001. Note for guidance on the investigation of bioavailability and bioequivalence. http://www.emea.eu.int/pdfs/human/ewp/140198en.pdf.
29. EMEA. 2008. Draft Guideline on the Investigation of Bioequivalence. CPMP/EWP/QWP/1401/98 Rev.1. (accessed May 18, 2009). http://www.emea.europa.eu/ pdfs/human/qwp/140198enrev1.pdf.
30. The United States Pharmacopeial Convention, Inc. 2009. USP;1; 32 - NF 27. The United States Pharmacopeia - The National Formulary, Rockville MD 2085.
31. Matsuda Y, Tatsumi E. 1990. Physicochemical characterization of furosemide modifications. Int J Pharm 60:11-26.
32. Beyers H, Malan SF, van der Watt JG, de Villiers MM. 2000. Structure-solubility relationship and thermal decomposition of furosemide. Drug Dev Ind Pharm 26:1077-1083.
33. Pudipeddi M, Serajuddin TM. 2005. Trends in solubility of polymorphs. J Pharm Sci 94:929-939.
34. Latosinska JN, Latosinska M, Medycki W, Osuchowicz J. 2006. Molecular dynamics of solid furosemide (4-chloro-2- furfurylamino-5-sulfamoyl-benzoic acid) studied by NMR and DFT methods. Chem Phy Lett 430:127-132. (Pubitemid 44465854)
35. Berthod A. 1999. Hydrophobicity of ionizable compounds. A theoretical study and measurements of diuretic octanol-water partition coefficients by countercurrent chromatography. Anal Chem 71:879-888.
36. Ruiz-Angel MJ, Carda-Broch SC, García-Alvarez-coque MC, Berthod A. 2004. Micellar versus hydro-organic mobile phases for retention-hydrophobicity relationship studies with ionizable diuretics and an anionic surfactant. J Chromatogr A 1030:279-288. (Pubitemid 38221340)
37. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. 2004. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1:85-96.
38. WHO.WHOmodel list of essential medicines. 16th list, March 2009. http://www.who.int/selection-medicines/committees/expert/17/WEB-unedited-16th- LIST.pdf. (accessed May 8, 2009).
39. ROTE LISTE® Arzneimittelverzeichnis für Deutschland. http://www.rote-liste.de. (accessed May 8, 2009).
40. The Danish Medicines Agency. http://www.dkma.dk. (accessed May 8, 2009).
41. National Agency for Medicines. http://www.nam.fi. (accessed May 15, 2009).
42. VIDAL. Fiches médicaments. http://www.vidal.fr. (accessed May 15, 2009).
43. College ter Beoordeling van Geneesmiddelen-Medicines Evaluation Board. http://www.cbg-meb.nl. (accessed May 8, 2009).
44. NorwegianMedicinesAgency. http://www.legemiddelverket.no. (accessed May 15, 2009).
45. Agencia Española de Medicamentos y Productos Sanitarios. http://www.agemed.es. (accessed May 15, 2009).
46. Läkemedelsverket. http://www.lakemedelsverket.se. (accessed May 15, 2009).
47. Datapharm Communications Ltd. http://www.medicines.org. uk. (accessed May 15, 2009).
48. DailyMed. http://www.dailymed.nlm.nih.gov. (accessed May 15, 2009).
49. Ponto LL, Schoenwald RD. 1990. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I). Clin Pharmacokinet 18:381-408.
50. Ponto LL, Schoenwald RD. 1990. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II). Clin Pharmacokinet 18:460-471.
51. Hammarlund MM, Paalzow LK, Odlind B. 1984. Pharmacokinetics of furosemide in man after intravenous and oral administration: Application of moment analysis. Eur J Clin Pharmacol 26:197-207. (Pubitemid 14130430)
52. Kelly MR, Cutler RE, Forrey AW, Kimpel BM. 1973. Pharmacokinetics of orally administered furosemide. Clin Pharmacol Ther 15:178-186.
53. Grahnén A, Hammarlund M, Lundqvist T. 1984. Implications of intraindividual variability in bioavailability studies of furosemide. Eur J Clin Pharmacol 27:595-602. (Pubitemid 15176768)
54. Chungi VS, Dittert LW, Smith RB. 1979. Gastrointestinal sites of furosemide absorption in rats. Int J Pharm 4:27-38.
55. Clear NJ, Milton A, HumphreyM, Henry BT, Wulff M, Nichols DJ, Anziano RJ, Wilding I. 2001. Evaluation of the intelisite capsule to deliver theophylline and frusemide tablets to the small intestine and colon. Eur J Pharm Sci 13:375-384. (Pubitemid 32618646)
56. Waller ES, Crismon M, Smith R, Bauga M, Doluisio J. 1988. Comparative bioavailability of furosemide from solution and 40mg tablets with different dissolution characteristics following oral administration in normal men. Biopharm Drug Dis 9:211-218. (Pubitemid 18079352)
57. McNamara PJ, Foster TS, Digenis GA, Patel RB, Craig WA, Welling PG, Rapaka RS, Prasad VK, Shah VP. 1987. Influence of tablet dissolution of furosemide bioavailability: A bioequivalence study. Pharm Res 4:150-153.
58. Kelly MR, Cutler RE, Forrey AW, Kimpel BM. 1973. Pharmacokinetics of orally administered furosemide. Clin Pharmacol Ther 15:178-186.
59. Cutler RE, Blair AD. 1979. Clinical pharmacokinetics of frusemide. Clin Pharmacokinet 4:279-296.
60. Beermann B, Midskov C. 1986. Reduced bioavailability and effect of furosemide given with foof. Eur J Clin Pharmacol 29:725-727. (Pubitemid 16155749)
61. Waller ES, Massarella JW, Tomkiw MS, Smith RV, Doluisio JT. 1985. Pharmacokinetics of furosemide after three different single oral doses. Biopharm Drug Dispos 6:109-117.
62. Smith DE, Lin ET, Benet LZ. 1980. Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite- specific assay. Drug Metab Dis 8:337-342.
63. Waller E, Hamilton SF, Massarella JW, Sharanevych MA, Smith RV, Yakatan GJ, Doluisio JT. 1982. Disposition and absolute bioavailability of furosemide in healthy males. J Pharm Sci 71:1105-1108. (Pubitemid 12032671)
64. Lennernas H, Knutson L, Knutson T, Lesko L, Salmonson T, Amidon GL. 1995. Human effective permeability data for furosemide, hydrochlothiazide, ketoprofen and naproxen to be used in the proposed biopharmaceutical classification for IR products. Pharm Res 12:S-396.
65. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, Tokuda H. 2000. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci 10:195-204. (Pubitemid 30190095)
66. Corti G, Maestrelli F, Cirri M, Zerrouk N, Mura P. 2006. Development and evaluation of an in vitro method for prediction of human drug absorption II. Demonstration on the method suitability. Eur J Pharm Sci 27:354-362. (Pubitemid 43143261)
67. Jung SJ, Choi SO, Um SY, Il Kim JI, Choo HYP, Cho SYi, Chung SY. 2006. Prediction of the permeability of drugs through study on quantitative structure-permeability relationship. J Pharm Biom Anal 41:469-475.
68. Flanagan SD, Benet LZ. 1999. Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco-2 monolayers and excised rat Jejunum. Pharm Res 16:221-224.
69. Pade V, Stavchansky S. 1997. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in Caco-2 cell culture model. Pharm Res 14:1210-1215. (Pubitemid 27432545)
70. Rege BD, Yu LX, Hussain AS, Polli JE. 2001. Effect of common excipients on Caco-2 transport of low-permeability drugs. J Pharm Sci 90:1776-1786.
71. Hilgendorf C, Spahn-Langguth H, Regardh CG, Lipka E, Amidon GL, Langguth P. 2000. Caco-2 versus Caco-2/HT29- MTX co-cultured cell lines: Permeabilities via diffusion, inside- and outside directed carrier-mediated transport. J Pharm Sci 89:63-75.
72. Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennernäs H, Karlén A. 1998. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem 41:4939-4949. (Pubitemid 28555452)
73. Collnot EM, Baldes C, Wempe MF, Hyatt J, Navarro L, Edgar KJ, Friedrich Schaeffer U, Lehr CM. 2006. Influence of vitamin ETPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J Control Release 111:35-40. (Pubitemid 43289992)
74. Beermann B, Dalen E, Lindstrom B. 1978. Bioavailability of two furosemide preparations. Br J Clin Pharmacol 6:537-538.
75. Eggers NJ, Kingsford M, Saint Joly CM, Jellett LB, Maling TJ. 1980. Bioavailability of furosemide.NZ Med J 91:403-404.
76. HabermannW, Rudolph F. 1980. Bioequivalence studies with furosemide. N Z Med J 92:476.
77. Martin BK, Uihlein M, Ings RM, Stevens LA, McEwen J. 1984. Comparative bioavailability of two furosemide formulations in humans. J Pharm Sci 73:437-441. (Pubitemid 14134313)
78. Straughn AB, Wood GC, Raghow G, Meyer MC. 1986. Bioavailability of seven furosemide tablets in man. Biopharm Drug Dis 7:113-120. (Pubitemid 16103274)
79. Kaojarern S, Poobrasert O, Utiswannakul A, Kositchaiwat U. 1990. Bioavailability and pharmacokinetics of furosemide marketed in Thailand. J Med Assoc Thai 73:191-197. (Pubitemid 20345291)
80. Awad R, Arafat T, Saket M, Saleh M, Gharaibeh M, Zmeili S, Sallam E, Shubair M, Qobrosi S. 1992. A bioequivalence study of two products of furosemide tablets. Int J Clin Pharmacol Ther Toxicol 30:18-23.
81. Nakib N, Idkaidek N, Beshtawi M, Bader M, Admour I, Alam SM, Zaman Q, Dham R. 2003. Bioequivalence evaluation of two brands of furosemide 40mg tablets (Salurin and Lasix) in healthy human volunteers. Biopharm Drug Dis 24:245-249. (Pubitemid 37160611)
82. Cuadrado A, Rodríguez Gascón A, Hernández RM, Castilla AM, de la Maza A, Yánez C, López de Ocáriz A, Solinís MA, Pedraz JL. 2003. In vivo pharmacokinetic-pharmacodynamic relationship and in vitro equivalence of two oral furosemide tablet formulations. Arzneimittelforschung Drug Res 53:321-329.
83. Yu LX. 2004. BioINequivalence: Concept and Definition. ACPS Meeting, October 19-20. http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4078 S2-07-YU.ppt. (accessed October 25, 2009).
84. Wolf-Coporda A, Lovrić Z, Huić M, Francetić I, Vrhovac B, Plavsić F, Skreblin M. 1996. Determination of bioequivalence of two furosemide preparations; the effect of high doses of furosemide on some pharmacokinetic parameters. Int J Clin Pharmacol Res 16:83-88. (Pubitemid 27217777)
85. Rubinstein MH, Rughani JM. 1978. The effect of four tablet binders on the bioavailability of frusemide from 40MG tablets. Drug Dev Ind Pharm 4:541-553. (Pubitemid 9123621)
86. Stüber W, Mutschler E, Steinbach D. 1982. The pharmaceutical and biological availability of commercial preparations of furosemide. Arzneimittelforschung Drug Res 32:693-697. (Pubitemid 12092988)
87. Prasad VK, Rapaka RS, Knight PW, Cabana BE. 1982. Dissolution medium - A critical parameter to identify bioavailability problems of furosemide tablets. Int J Pharm 11:81-90.
88. Kingsford M, Eggers NJ, Soteros G. 1984. An in vivo-in vitro correlation for the bioavailability of frusemide tablets. J Pharm Pharmacol 36:536-538. (Pubitemid 14096775)
89. Qureshi SA, McGilveray IJ. 1998. Assessment of pharmaceutical quality of furosemide tablets from multinational markets. Drug Dev Ind Pharm 24:995-1005.
90. WHO. 2006. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. Technical Report Series, No937, 40th Report, Annex 8 of WHO Expert committee on specifications for pharmaceutical preparations. http://whqlibdoc.who.int/trs/ WHO-TRS-937-eng.pdf. (accessed July 22, 2009).
91. Hammarlund-Idemaes M, Benet LZ. 1989. Furosemide pharmacokinetics and pharmacodynamics in health and disease - An update. J Biopharmacokinet Biopharm 17:1-46. (Pubitemid 19111988)
92. Artursson P, Palm K, Luthaman K. 2001. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Del Rev 46:27-43. (Pubitemid 33653412)
93. Rinaki E, Valsami G, Macheras P. 2003. Quantitative biopharmaceutics classification system: The central role of dose/ solubility ratio. Pharm Res 20:1917-1925. (Pubitemid 38005521)
94. Gres M-C, Julian B, Bourre M, Meunier V, Roques C, Berger M, Boulenc X, Berger Y, Fabre G. 1998. Correlation between oral drug absorption in humans and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: Comparison with the parental Caco-2 cell line. Pharm Res 15:726-733. (Pubitemid 28275649)
95. Lindenberg M, Kopp S, Dressman JB. 2004. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pham Biopharm 58:265-278. (Pubitemid 39037234)
96. Wu C-Y, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
97. Schulz M, Schmoldt A. 2003. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58:447-474. (Pubitemid 36869876)
98. FDA. Code of Federal Regulations. Title 21, Part 320: Bioavailability and Bioequivalence requirements. Section 320.33. 2003. http://www.accessdata.fda. gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=320.33. (accessed May 18, 2009).
99. PAHO. Science based criteria for bioequivalence in vivo and in vitro, biowaivers, and strategic framework for implementation. http://www.paho.org/ english/ad/ths/ev/be-doct-drafteng.pdf. (accessed May 18, 2009).
100. FDA. 2005. Guidance for Industry. Immediate Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation. (SUPAC-IR). www.fda.gov/cder/guidance/supac.htm.
101. European Commission. 2006. Guideline on Dossier requirements for Type IA and Type IB. http://ec.europa.eu/enterprise/ pharmaceuticals/eudralex/vol-2/c/ var-type-1a1b-guideline-06-2006.pdf.